-
Je něco špatně v tomto záznamu ?
Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma
I. Baranova, H. Kovarikova, J. Laco, I. Sedlakova, F. Vrbacky, D. Kovarik, P. Hejna, V. Palicka, M. Chmelarova
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
PubMed
32145055
DOI
10.1515/cclm-2019-1319
Knihovny.cz E-zdroje
- MeSH
- časná detekce nádoru MeSH
- lidé MeSH
- metylace DNA * MeSH
- nádorové biomarkery krev MeSH
- nádory vaječníků krev diagnóza genetika MeSH
- senzitivita a specificita MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early in the cancer development, they provide great potential to serve as such biomarkers. In our study, we investigated a potential of a four-gene methylation panel (including CDH13, HNF1B, PCDH17 and GATA4 genes) for the early detection of high-grade serous ovarian carcinoma (HGSOC). Methods For methylation detection we used methylation sensitive high-resolution melting analysis and real-time methylation specific analysis. We also investigated the relation between gene hypermethylation and gene relative expression using the 2-ΔΔCt method. Results The sensitivity of the examined panel reached 88.5%. We were able to detect methylation in 85.7% (12/14) of early stage tumors and in 89.4% (42/47) of late stage tumors. The total efficiency of the panel was 94.4% and negative predictive value reached 90.0%. The specificity and positive predictive value achieved 100% rates. Our results showed lower gene expression in the tumor samples in comparison to control samples. The more pronounced downregulation was measured in the group of samples with detected methylation. Conclusions In our study we designed the four-gene panel for HGSOC detection in ovarian tissue with 100% specificity and sensitivity of 88.5%. The next challenge is translation of the findings to the less invasive source for biomarker examination, such as plasma. Our results indicate that combination of examined genes deserve consideration for further testing in clinical molecular diagnosis of HGSOC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026640
- 003
- CZ-PrNML
- 005
- 20211026132732.0
- 007
- ta
- 008
- 211013s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1515/cclm-2019-1319 $2 doi
- 035 __
- $a (PubMed)32145055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Baranova, Ivana $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 245 10
- $a Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma / $c I. Baranova, H. Kovarikova, J. Laco, I. Sedlakova, F. Vrbacky, D. Kovarik, P. Hejna, V. Palicka, M. Chmelarova
- 520 9_
- $a Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early in the cancer development, they provide great potential to serve as such biomarkers. In our study, we investigated a potential of a four-gene methylation panel (including CDH13, HNF1B, PCDH17 and GATA4 genes) for the early detection of high-grade serous ovarian carcinoma (HGSOC). Methods For methylation detection we used methylation sensitive high-resolution melting analysis and real-time methylation specific analysis. We also investigated the relation between gene hypermethylation and gene relative expression using the 2-ΔΔCt method. Results The sensitivity of the examined panel reached 88.5%. We were able to detect methylation in 85.7% (12/14) of early stage tumors and in 89.4% (42/47) of late stage tumors. The total efficiency of the panel was 94.4% and negative predictive value reached 90.0%. The specificity and positive predictive value achieved 100% rates. Our results showed lower gene expression in the tumor samples in comparison to control samples. The more pronounced downregulation was measured in the group of samples with detected methylation. Conclusions In our study we designed the four-gene panel for HGSOC detection in ovarian tissue with 100% specificity and sensitivity of 88.5%. The next challenge is translation of the findings to the less invasive source for biomarker examination, such as plasma. Our results indicate that combination of examined genes deserve consideration for further testing in clinical molecular diagnosis of HGSOC.
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 12
- $a metylace DNA $7 D019175
- 650 _2
- $a časná detekce nádoru $7 D055088
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory vaječníků $x krev $x diagnóza $x genetika $7 D010051
- 650 _2
- $a senzitivita a specificita $7 D012680
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kovarikova, Helena $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Sedlakova, Iva $u Department of Obstetrics and Gynecology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Vrbacky, Filip $u The 4th Department of Internal Medicine - Hematology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kovarik, Dalibor $u Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Hejna, Petr $u Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Chmelarova, Marcela $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 58, č. 8 (2020), s. 1332-1340
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32145055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132738 $b ABA008
- 999 __
- $a ok $b bmc $g 1715392 $s 1147147
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 58 $c 8 $d 1332-1340 $e 20200728 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
- LZP __
- $a Pubmed-20211013